Because of the significance and severity of atherosclerosis, and the company's belief that nanobacteria might play a key role in its development, Nanobac focused its early efforts on investigating the relationship between nanobacteria and atherosclerosis. This release is intended to summarize what has been determined thus far, and what remains to be done.
Three recently published studies conducted by prominent medical researchers have collectively shown that nanobacteria might be the previously unidentified agent involved in the development of atherosclerotic heart disease. A group of researchers at Mayo Clinic, led by Virginia Miller, PhD, showed that nanobacteria are present in calcified atherosclerotic coronary arteries and heart valves.
In September 2004, cardiovascular researcher Benedict Maniscalco, MD published a study showing that patients with severe coronary artery heart disease tested positive for nanobacterial antigen. The study also indicates that a majority of cardiac patients who received Tetracycline, EDTA (Nanobac Life Sciences,
Finally, at a recent American Heart Association scientific session in New Orleans, one of the world's most prominent heart disease researchers, Stephen E. Epstein, MD, director of the Cardiovascular Research Institute at Washington Hospital Medical Center in DC, reported that 94 percent of people with calcified coronary arteries have nanobacterial infection as measured by Nanobac's Nanobacterial Antibody Assay, and that antibody results correlated with coronary calcification scoring.
The collective weight of the three studies suggests that nanobacteria infection is arguably the previously unknown infectious agent associated with atherosclerotic plaque. Since nanobacteria are physically present in the diseased atherosclerotic tissues and are statistically correlated with heart disease calcification levels, it is also reasonable to assume that long term nanobacteria infection is involved in the development of the calcification in atherosclerotic heart disease.
Currently, atherosclerosis is a lifelong disease process that can lead to debilitating coronary artery heart disease, kidney disease, and many other chronic diseases. Early diagnosis and treatment of nanobacterial infections may ultimately lead to early recognition of heart disease.
The company continues to research the relationship between nanobacterial infection and heart disease, and has expanded its research to include other diseases involving pathological calcification. The company is seeking to collaborate, partner, or joint venture with other entities to further evaluate, test and commercialize both its diagnostic and therapeutic products and pipeline. The company is in the process of identifying, negotiating, and concluding these relationships.
Source: Nanobac Life Sciences, Inc.